Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Therapeutic targets, novel drugs, and delivery systems for diabetes associated NAFLD and liver fibrosis
Virender Kumar, Xiaofei Xin, Jingyi Ma, et al.
Advanced Drug Delivery Reviews (2021) Vol. 176, pp. 113888-113888
Open Access | Times Cited: 109

Showing 1-25 of 109 citing articles:

Fibroblasts: Immunomodulatory factors in refractory diabetic wound healing
Ye Liu, Yiqiu Liu, Wenjie He, et al.
Frontiers in Immunology (2022) Vol. 13
Open Access | Times Cited: 94
MicroRNAs in non-alcoholic fatty liver disease: Progress and perspectives
Mette Yde Hochreuter, Morten Dall, Jonas T. Treebak, et al.
Molecular Metabolism (2022) Vol. 65, pp. 101581-101581
Open Access | Times Cited: 85
Association between the cardiometabolic index and NAFLD and fibrosis
Laisha Yan, Xiao Hu, Shanshan Wu, et al.
Scientific Reports (2024) Vol. 14, Iss. 1
Open Access | Times Cited: 19
NAFLD and NAFLD Related HCC: Emerging Treatments and Clinical Trials
Tushar Khare, Karina Liu, Lindiwe Oslee Chilambe, et al.
International Journal of Molecular Sciences (2025) Vol. 26, Iss. 1, pp. 306-306
Open Access | Times Cited: 4
Cigarette Smoke Contributes to the Progression of MASLD: From the Molecular Mechanisms to Therapy
Jihao Xu, Yifan Li, Zhaolan Feng, et al.
Cells (2025) Vol. 14, Iss. 3, pp. 221-221
Open Access | Times Cited: 2
Progress and Challenges in Targeted Protein Degradation for Neurodegenerative Disease Therapy
Yingxu Fang, Jiaxing Wang, Min Zhao, et al.
Journal of Medicinal Chemistry (2022) Vol. 65, Iss. 17, pp. 11454-11477
Closed Access | Times Cited: 49
Tracking Cell Viability for Adipose-Derived Mesenchymal Stem Cell-Based Therapy by Quantitative Fluorescence Imaging in the Second Near-Infrared Window
Naishun Liao, Lichao Su, Yanbing Cao, et al.
ACS Nano (2022) Vol. 16, Iss. 2, pp. 2889-2900
Closed Access | Times Cited: 40
Restoration of Sinusoid Fenestrae Followed by Targeted Nanoassembly Delivery of an Anti‐Fibrotic Agent Improves Treatment Efficacy in Liver Fibrosis
Fenfen Li, Ying Zhao, Zhaoxia Cheng, et al.
Advanced Materials (2023) Vol. 35, Iss. 17
Closed Access | Times Cited: 36
Obesity, non-alcoholic fatty liver disease and hepatocellular carcinoma: current status and therapeutic targets
Yinshuang Chen, Weipeng Wang, Maria P. Morgan, et al.
Frontiers in Endocrinology (2023) Vol. 14
Open Access | Times Cited: 30
Activation of Kupffer cells in NAFLD and NASH: mechanisms and therapeutic interventions
Gao-Xin Xu, Wei Song, Chao Yu, et al.
Frontiers in Cell and Developmental Biology (2023) Vol. 11
Open Access | Times Cited: 29
Nonalcoholic fatty liver disease: Current therapies and future perspectives in drug delivery
Inês Domingues, Isabelle Leclercq, Ana Beloqui
Journal of Controlled Release (2023) Vol. 363, pp. 415-434
Closed Access | Times Cited: 28
Emerging trends and hotspots in metabolic dysfunction-associated fatty liver disease (MAFLD) research from 2012 to 2021: A bibliometric analysis
Yudi Liao, Liya Wang, Fang Liu, et al.
Frontiers in Endocrinology (2023) Vol. 14
Open Access | Times Cited: 24
Benefits and risks of drug combination therapy for diabetes mellitus and its complications: a comprehensive review
Xueqin Xie, Changchun Wu, Yuduo Hao, et al.
Frontiers in Endocrinology (2023) Vol. 14
Open Access | Times Cited: 24
The cGAS-STING pathway: a therapeutic target in diabetes and its complications
Wenjie He, Xingrui Mu, Xingqian Wu, et al.
Burns & Trauma (2024) Vol. 12
Open Access | Times Cited: 14
Deficiency of ASGR1 promotes liver injury by increasing GP73-mediated hepatic endoplasmic reticulum stress
Zhe Zhang, X. Leng, Yuan Zhai, et al.
Nature Communications (2024) Vol. 15, Iss. 1
Open Access | Times Cited: 14
Nanotechnology in Drug Delivery for Liver Fibrosis
Lihong Gu, Feng Zhang, Jinhui Wu, et al.
Frontiers in Molecular Biosciences (2022) Vol. 8
Open Access | Times Cited: 38
Pharmacotherapy for Non-Alcoholic Fatty Liver Disease: Emerging Targets and Drug Candidates
V. A. Prikhodko, Natalia N. Bezborodkina, Sergey V. Okovityi
Biomedicines (2022) Vol. 10, Iss. 2, pp. 274-274
Open Access | Times Cited: 37
Recent Advances in Stimuli-Responsive Doxorubicin Delivery Systems for Liver Cancer Therapy
Elena Radu, Augustin Semenescu, Ștefan Ioan Voicu
Polymers (2022) Vol. 14, Iss. 23, pp. 5249-5249
Open Access | Times Cited: 34
The Global, Regional, and National Burden and Trends of NAFLD in 204 Countries and Territories: An Analysis From Global Burden of Disease 2019
Huilong Chen, Yuan Zhan, Jinxiang Zhang, et al.
JMIR Public Health and Surveillance (2022) Vol. 8, Iss. 12, pp. e34809-e34809
Open Access | Times Cited: 32
Dually fibronectin/CD44-mediated nanoparticles targeted disrupt the Golgi apparatus and inhibit the hedgehog signaling in activated hepatic stellate cells to alleviate liver fibrosis
Yanping Li, Ting Zhang, Jinhang Zhang, et al.
Biomaterials (2023) Vol. 301, pp. 122232-122232
Closed Access | Times Cited: 19
Single-cell RNA sequencing reveals cell subpopulations in the tumor microenvironment contributing to hepatocellular carcinoma
Jiamin Gao, Zhijian Li, Qinchen Lu, et al.
Frontiers in Cell and Developmental Biology (2023) Vol. 11
Open Access | Times Cited: 18
Examining the Pathogenesis of MAFLD and the Medicinal Properties of Natural Products from a Metabolic Perspective
Yansong Fu, Zhipeng Wang, Hong Qin
Metabolites (2024) Vol. 14, Iss. 4, pp. 218-218
Open Access | Times Cited: 8
Oxymatrine alleviates high-fat diet/streptozotocin-induced non-alcoholic fatty liver disease in C57BL/6 J mice by modulating oxidative stress, inflammation and fibrosis
Di Lou, Qing Fang, Yinghao He, et al.
Biomedicine & Pharmacotherapy (2024) Vol. 174, pp. 116491-116491
Open Access | Times Cited: 6
Punicalagin Ameliorates Diabetic Liver Injury by Inhibiting Pyroptosis and Promoting Autophagy via Modulation of the FoxO1/TXNIP Signaling Pathway
Xiuying Tan, Long Yi, Rou Zhang, et al.
Molecular Nutrition & Food Research (2024) Vol. 68, Iss. 12
Closed Access | Times Cited: 6
Jujuboside A through YY1/CYP2E1 signaling alleviated type 2 diabetes-associated fatty liver disease by ameliorating hepatic lipid accumulation, inflammation, and oxidative stress
Wenjing Zhang, Cheng Qian, Longxiang Yin, et al.
Chemico-Biological Interactions (2024) Vol. 400, pp. 111157-111157
Closed Access | Times Cited: 6
Page 1 - Next Page

Scroll to top